Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;115(2):153-157.
doi: 10.1007/s12185-021-03285-6. Epub 2022 Jan 6.

Isolated thrombosis after COVID-19 vaccination: case series

Mona Al-Ahmad  1   2 , Mona Al Rasheed  3 , Lulwa Altourah  3 , Tito Rodriguez-Bouza  4 , Neveen Shalaby  3
Affiliations

Isolated thrombosis after COVID-19 vaccination: case series

Mona Al-Ahmad et al. Int J Hematol. 2022 Feb.

Abstract

Background: Data regarding thrombosis after COVID-19 vaccination are scarce.

Methods: Clinical and laboratory data were collected from all patients who developed thrombosis within 4 weeks of receiving the Pfizer or Oxford/AstraZeneca vaccine. None had a COVID-19-positive swab.

Results: Seventeen patients were included, with average age of 48.8 years and equal proportion of females to males. Our data suggest that thrombosis occurred in 1 in 163,000 of all individuals who had received any dose of any type of COVID-19 vaccine: six (1 in 123,000) patients after the first dose of Oxford/AstraZeneca, none after the second dose of Oxford/AstraZeneca, four (1 in 257,000) patients after the first dose of the Pfizer vaccine, and seven (1 in 102,000) patients after the second dose of Pfizer vaccine. Three of 17 patients with thrombosis (17.6%) died.

Conclusions: We believe this report to be one of the earliest in the literature to address the question of whether isolated thrombosis is a possible complication of COVID-19 vaccination.

Keywords: COVID-19; Thrombosis; Vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Similar articles

See all similar articles

Cited by

References

    1. Chi G, Lee JJ, Jamil A, Gunnam V, Najafi H, Memar Montazerin S, et al. Venous thromboembolism among hospitalized patients with COVID-19 undergoing thromboprophylaxis: a systematic review and meta-analysis. J Clin Med. 2020;9(8):2489. doi: 10.3390/jcm9082489. - DOI - PMC - PubMed
    1. Criel M, Falter M, Jaeken J, Van Kerrebroeck M, Lefere I, Meylaerts L, et al. Venous thromboembolism in SARS-CoV-2 patients: only a problem in ventilated ICU patients, or is there more to it? Eur Respir J. 2020;56(1):2001201. 10.1183/13993003.01201-2020. Accessed 30 Jul 2020. - PMC - PubMed
    1. Mohamed MFH, Al-Shokri SD, Shunnar KM, Mohamed SF, Najim MS, Ibrahim SI, et al. Prevalence of venous thromboembolism in critically Ill COVID-19 patients: systematic review and meta-analysis. Front Cardiovasc Med. 2020;7:598846. doi: 10.3389/fcvm.2020.598846. - DOI - PMC - PubMed
    1. Marietta M, Ageno W, Artoni A, De Candia E, Gresele P, Marchetti M, et al. COVID-19 and haemostasis: a position paper from Italian Society on thrombosis and haemostasis (SISET) Blood Transfus. 2020;18(3):167–169. - PMC - PubMed
    1. Spyropoulos AC, Levy JH, Ageno W, Connors JM, Hunt BJ, Iba T, et al. Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1859–1865. doi: 10.1111/jth.14929. - DOI - PMC - PubMed